Related Experiment Video
Updated: Mar 22, 2026
Assessing Whole-Body Lipid-Handling Capacity in Mice
Published on: November 24, 2020
Diabetic Dyslipidemia Review: An Update on Current Concepts and Management Guidelines of Diabetic Dyslipidemia
Andrew W Dake1, Nicoleta D Sora1
1Division of Endocrinology, Diabetes and Medical Genetics, Medical University of South Carolina, Charleston, South Carolina.
Insights
Managing dyslipidemia in diabetes is crucial for reducing cardiovascular disease. Cholesterol-lowering guidelines vary, but offer tools to personalize treatment for diabetic patients.
Area of Science:
- Endocrinology
- Cardiology
- Metabolic Disorders
Background:
- Cardiovascular disease (CVD) is a primary cause of death and cost in diabetes management.
- Dyslipidemia treatment with cholesterol-lowering drugs reduces cardiovascular events.
- Existing dyslipidemia treatment guidelines present notable discrepancies.
Purpose of the Study:
- To review and compare major lipid guidelines concerning diabetes management.
- To explore the unique lipid profile (phenotype) in diabetic patients.
- To examine the relationship between statin use and the onset of new diabetes.
Main Methods:
- Review of lipid guidelines from NCEP ATP III, AACE, ADA, and AHA/ACC.
- PubMed literature search for diabetic dyslipidemia peculiarities.
- Analysis of guideline recommendations and relevant research.
Main Results:
- Summary of key guidelines for diabetes and dyslipidemia.
- Discussion of the diabetic dyslipidemia phenotype.
- Examination of the association between statins and new-onset diabetes.
Conclusions:
- Disparities in guidelines can cause confusion for clinicians.
- Guidelines serve as valuable tools for individualized patient treatment plans.
- Personalized treatment is essential for managing dyslipidemia in diabetic patients.
Background:
Cardiovascular disease is the most common cause of morbidity and mortality in patients with diabetes and the major source of cost in the care of diabetes. Treatment of dyslipidemia with cholesterol-lowering medications has been shown to decrease cardiovascular events. However, available guidelines for the treatment of dyslipidemia often contain significant differences in their recommendations.
Methods:
Lipid guidelines from National Cholesterol Education Program Adult Treatment Panel III, American Association of Clinical Endocrinologists, American Diabetes Association and American Heart Association/American College of Cardiology were reviewed. In addition a literature review was performed using PubMed to research diabetic peculiarities to the topic of lipids.
Results:
Summarized within this article are the aforementioned, commonly-used guidelines as they relate to diabetes, as well as information regarding the diabetic phenotype of dislipidemia and the association between statins and new-onset diabetes.
Conclusions:
While the multitude of guidelines and the differences between them may contribute to confusion for practitioners, they are best viewed as tools to help tailor appropriate treatment plans for individual patients.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:26Atherosclerosis III: Management
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:24Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:26Angina IV: Management
01:15Diabetes: Symptoms, Diagnosis, and Complications